Reem Karmali, MD
The non–Hodgkin lymphoma landscape recently underwent a major transformation, as researchers in the field saw the FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for transplant-ineligible patients with relapsed or refractory disease.
on Hematologic Malignancies, Karmali, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discussed ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.
OncLive: There have been several developments in CAR T-cell therapy over the last few months. What did you share in your presentation?
We went through a little bit of an overview of immunotherapy as a segue to CAR T-cell therapy, and then, with respect to CAR T cells, we talked about the construct itself, its mechanism of action, and then we spoke about some of the key clinical trials for CAR T-cell therapy—specifically focusing on some of the encouraging results we are seeing in DLBCL.
... to read the full story